💰 Financial Performance

Revenue Growth by Segment

Revenue grew 25.8% YoY to INR 10,391.5 Lacs in FY25. Segment performance in FY25: Tablets reached INR 67 Cr (up 34% from INR 50 Cr), ORS reached INR 16 Cr (up 77.7% from INR 9 Cr), Suspensions reached INR 10 Cr (up 25% from INR 8 Cr), Syrups reached INR 9 Cr (up 350% from INR 2 Cr), and Ointments reached INR 8 Cr (up 33.3% from INR 6 Cr).

Geographic Revenue Split

Primarily domestic-focused with 100% of historical revenue from India; however, the company initiated export sales in 2025 to diversify revenue streams and target international markets.

Profitability Margins

Gross Profit Margin declined from 36.7% in FY24 to 23.8% in FY25 due to a 51.5% surge in raw material costs. Net Profit Margin (PAT) improved from 12.2% in FY24 to 13.1% in FY25, driven by higher other income of INR 424.4 Lacs and operational efficiencies.

EBITDA Margin

EBITDA Margin was 15.4% in FY25, a decrease of 340 bps from 18.8% in FY24. Core profitability was impacted by raw material costs rising to 76.2% of revenue in FY25 compared to 63.3% in FY24.

Capital Expenditure

Planned CAPEX includes INR 26.00 Cr from IPO proceeds for plant and machinery expansion, with INR 2.74 Cr utilized as of May 2025. Additional investment is directed toward a USFDA-compliant injectable facility at Plot 44, Pithampur, acquired on April 7, 2025.

Credit Rating & Borrowing

Finance costs increased 18.6% YoY to INR 90.6 Lacs in FY25. Total borrowings stood at INR 3,025.78 Lacs as of March 31, 2025, primarily driven by a sharp increase in short-term borrowings to INR 2,890.10 Lacs.

⚙️ Operational Drivers

Raw Materials

Specific chemical names not disclosed; however, 'Total Raw Material' represents the largest cost component at 76.2% of total revenue in FY25 (INR 7,915.9 Lacs).

Capacity Expansion

Setting up a new USFDA-compliant injectable facility with oncology, ampoule, vial, and dry injection lines. A new capsule production line is also in progress with an expected revenue contribution of INR 10-12 Cr in the current year.

Raw Material Costs

Raw material costs were INR 7,915.9 Lacs in FY25, representing 76.2% of revenue, a significant increase from 63.3% in FY24. This increase is a primary driver of gross margin compression.

Manufacturing Efficiency

3-year EBITDA CAGR of 35.2% and PAT CAGR of 48.9% suggest improving manufacturing scale and efficiency despite raw material headwinds.

📈 Strategic Growth

Expected Growth Rate

30%

Growth Strategy

Growth will be achieved through a three-pronged strategy: 1) Expanding domestic sales to hit a 30% growth target, 2) Commissioning a new USFDA-compliant injectable and oncology plant at Pithampur, and 3) Launching a new capsule production line expected to generate INR 10-12 Cr annually.

Products & Services

Tablets, Syrups, Suspensions, Ointments, ORS (Oral Rehydration Salts), and upcoming Injectables and Oncology products.

Brand Portfolio

Quest Laboratories.

New Products/Services

Capsules (expected INR 10-12 Cr revenue) and Injectables/Oncology products (targeting both domestic and export markets).

Market Expansion

Initiated export sales in 2025; targeting global markets through USFDA-compliant manufacturing standards.

Strategic Alliances

Engaged a specialized pharma consultant for the design and development of the new Pithampur oncology and injectable plant.

🌍 External Factors

Industry Trends

The industry is shifting toward specialized delivery systems like injectables and oncology. Quest is positioning itself by moving from basic oral solids (Tablets/Syrups) to complex USFDA-compliant injectables to capture higher value.

Competitive Landscape

Operates in a highly competitive domestic generic market; moving toward specialized segments to differentiate from local manufacturers.

Competitive Moat

Moat is being built through regulatory compliance (USFDA standards) and specialized manufacturing (Oncology/Injectables), which have higher entry barriers than standard generics.

Macro Economic Sensitivity

High sensitivity to pharmaceutical raw material inflation and regulatory compliance costs for USFDA standards.

Consumer Behavior

Increased demand for high-quality, compliant pharmaceutical products in both domestic and emerging export markets.

Geopolitical Risks

Potential trade barriers or regulatory changes in export markets as the company expands internationally.

⚖️ Regulatory & Governance

Industry Regulations

Compliance with the Companies Act 2013 and Section 135 (CSR). Manufacturing must adhere to USFDA standards for the new facility and Indian GMP for existing lines.

Taxation Policy Impact

Effective tax rate for FY25 was approximately 27.4% (INR 511.8 Lacs tax on INR 1,868.3 Lacs PBT).

Legal Contingencies

No material fraud or whistle-blower complaints reported during FY25. No specific pending court case values disclosed.

⚠️ Risk Analysis

Key Uncertainties

Raw material price volatility (impacted gross margins by ~1300 bps in FY25) and execution risk of the new Pithampur facility.

Geographic Concentration Risk

High concentration in India, though the 2025 export initiation aims to mitigate this.

Third Party Dependencies

Dependency on pharma consultants for the design of the USFDA-compliant facility.

Technology Obsolescence Risk

Risk of non-compliance with evolving USFDA or international manufacturing standards for injectables.

Credit & Counterparty Risk

Trade receivables increased 40.5% to INR 1,939.2 Lacs in FY25, indicating potential credit risk or lengthening collection cycles.